Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04839315 · ClinicalTrials.gov registry record · Early Phase 1

COVID-19 Vaccination in Rheumatic Disease Patients

A Early Phase 1 study, sponsored by Mayo Clinic.

Terminated
Registry status
Early Phase 1
Development phase
58
Enrollment target

NCT04839315: Clinical Trial Early Phase 1 study, sponsored by Mayo Clinic.

NCT04839315 is a Early Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04839315, a Early Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.

TERMINATED
Registry status
Early Phase 1
Development phase
58 participants
Enrollment target

Study Summary

The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.

Interventions

  • BIOLOGICAL mRNA COVD19 vaccine

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2021-02-15
Est. Completion 2022-02-09
Phase Early Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT04839315

The ClinicalTrials.gov registry entry for NCT04839315 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which mRNA COVD19 vaccine is the first listed.

NCT04839315 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04839315 about?

NCT04839315 is a clinical study titled "COVID-19 Vaccination in Rheumatic Disease Patients". The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.

What is the current status of trial NCT04839315?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 58 participants. The study started on 2021-02-15. Estimated completion is 2022-02-09.

What interventions are being tested in trial NCT04839315?

The interventions under investigation include: mRNA COVD19 vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT04839315?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.